• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2009
      • 7.1.1.3 2010
      • 7.1.1.4 2001
      • 7.1.1.5 2002
      • 7.1.1.6 2003
      • 7.1.1.7 2004
      • 7.1.1.8 2005
      • 7.1.1.9 2006
      • 7.1.1.10 2007
      • 7.1.1.11 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

Press Releases Company 2005
= Information for professionals with login

• Merz Pharmaceuticals Taps the Third Largest Pharmaceutical Market in Europe with Merz Italia (20 Oct 2005)

• Merz Pharma awarded certificate for family-friendly personnel policies (05 Sep 2005)

• Alzheimer´s Substance Memantine strenghtens worldwide market position (10 Aug 2005)

• Global Sales of Alzheimer’s Substance Memantine Exceeds 500 Million Euros (10 Aug 2005) 

• Patients with Vascular Dementia Benefit from Treatment with Memantine (13 Jun 2005) 

• New Publication on Alzheimer’s Disease Shows Patients with Behavioral Disturbances Benefit from Axura® (Memantine) (13 May 2005)

• Merz Pharmaceuticals: New Strategic Partnership strenghtens Product Portfolio in Aesthetic Dermatology (12 May 2005)

• Dr. Martin Zügel named Chief Executive Officer of Merz Pharmaceuticals GmbH, effective April 1, 2005 (08 Apr 2005)

• Switching to AXURA® from Acetylcholin-esterase-Inhibitor is safe and well tolerated (14 Mar 2005) 

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s